Recently, we described the development of a cryogel-supported cell factory suitable for a sustained delivery of an anti-CD33-anti-CD3 bsAb, that is capable of specifically and efficiently redirecting CD3+ T lymphocytes towards CD33+ AML blasts [42, 43]. This evidence concerns the gene CD33 and acute myeloid leukemia.